Predictor | Rate Ratio | 95% CI |
---|---|---|
Age | 0.99 | 0.98–1.01 |
Sex (Male) | 0.91 | 0.68–1.23 |
Race | ||
 White (versus non-White) | 0.97 | 0.52–1.82 |
 Black (versus non-Black) | 0.87 | 0.42–1.79 |
Employed | 2.84 | 2.05–3.95* |
Insured (versus uninsured)a | 1.14 | 0.76–1.71 |
Living location | ||
 Metro | 0.89 | 0.64–1.22 |
 Small | 1.47 | 0.98–2.19 |
 Rural | 1.83 | 1.04–3.21* |
Opioid-related baseline ED encounter | 1.22 | 0.86–1.73 |
Narcan administered pre-baseline encounter | 1.18 | 0.84–1.68 |
Preferred route of administration | ||
 Intravenous | 0.87 | 0.66–1.16 |
 Oral ingestion | 1.15 | 0.85–1.54 |
 Inhalation/Snorting | 1.27 | 0.89–1.82 |
 Smoking | 0.64 | 0.38–1.07 |
Total referrals (number) | 1.08 | 0.99–1.18 |
Any referrals (at least one versus none) | ||
 All referral types | 1.64 | 1.20–2.24* |
 Inpatient services | 0.77 | 0.51–1.14 |
 Residential services | 0.62 | 0.32–1.23 |
 Outpatient treatment | 2.08 | 1.60–2.71* |
 Detox | 0.75 | 0.49–1.15 |
 Peer support group | 1.38 | 0.96–2.00 |
 Medication for opioid use disorder | 1.39 | 0.78–2.49 |
Number ED encounters in previous 365 days | 0.99 | 0.98–0.99* |
Baseline telehealth interaction call (in minutes) | 0.87 | 0.85–0.88* |